The present specification relates to a double spiro structure compound, and an organic light emitting device comprising the same.

The present specification relates to a double spiro structure compound, and an organic light emitting device comprising the same.

A composition for forming organic film, a display device utilizing the composition, and a method of manufacturing the display device are provided. The composition for forming an organic film includes a solvent; and a compound of Formula 1:
ArR).sub.k.  Formula 1

A composition for forming organic film, a display device utilizing the composition, and a method of manufacturing the display device are provided. The composition for forming an organic film includes a solvent; and a compound of Formula 1:
ArR).sub.k.  Formula 1

The invention relates to compounds of Formula (I)

##STR00001##

wherein X.sup.1, X.sup.2, X.sup.3, Y, R.sup.1, R.sup.2A, R.sup.2B, R.sup.3, and R.sup.4 are as described in the description; to their preparation, to pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing one or more compounds of Formula (I), and to the use of such compounds as medicaments, especially as Kv7 openers.

Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of Olig2. Also described herein are methods of using such Olig2 inhibitors, alone and in combination with other compounds, for treating cancer and other diseases. In particular the Olig2 inhibitors may be used to treat glioblastoma.

The present disclosure relates to bifunctional compounds, which find utility to degrade (and inhibit) Androgen Receptor. In particular, the present disclosure is directed to compounds, which contain on one end a cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds Androgen Receptor, such that Androgen Receptor is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of Androgen Receptor. The present disclosure exhibits a broad range of pharmacological activities associated with compounds according to the present disclosure, consistent with the degradation/inhibition of Androgen Receptor.

The present disclosure relates to bifunctional compounds, which find utility to degrade (and inhibit) Androgen Receptor. In particular, the present disclosure is directed to compounds, which contain on one end a cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds Androgen Receptor, such that Androgen Receptor is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of Androgen Receptor. The present disclosure exhibits a broad range of pharmacological activities associated with compounds according to the present disclosure, consistent with the degradation/inhibition of Androgen Receptor.

The invention relates to substituted pyridine and pyrimidine compounds of Formula (I) and the pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein R.sup.1, R.sup.2a, R.sup.2b, A.sup.1, A.sup.2, X, and Z are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of sodium channels. Compounds of the present invention are especially useful for treating pain. ##STR00001##

The present specification relates to a double spiro structure compound, and an organic light emitting device comprising the same.